Pseudohypoparathyroidism (PHP) is a rare inherited syndrome characterized by parathyroid hormone (PTH) resistance and is frequently associated with Albright’s hereditary osteodystrophy and resistance to other cAMP-mediated hormones. The usual neonatal presentation is mild primary hypothyroidism secondary to resistance to thyroid-stimulating hormone; hypocalcemia usually develops after age 3–5 years. This work describes the diversity in the clinical expression and course of PHP, with emphasis on calcium levels by age and treatment, in 8 children under long-term follow-up at our pediatric tertiary center. The calcium levels at presentation ranged from transient neonatal hypocalcemia to infantile hypercalcemia to childhood/adolescence hypocalcemia. Interestingly, relative hypocalciuria at diagnosis and during therapy, in the presence of renal PTH resistance, was the rule. These findings indicate that transient neonatal hypocalcemia associated with other clinical features or a family history of PHP may be a flag for clinicians to screen for PTH resistance later in life. In addition, PTH resistance may be missed by surveying calcium levels only; thus the PTH levels have to be checked as well. In addition, the recommendation for patients with hypoparathyroidism that strict low-normal calcium levels be maintained during therapy in order to prevent hypercalciuria is probably not applicable in PHP.

Keywords:
Hyper-/hypocalcemia, Hypocalciuria, Pseudohypoparathyroidism
1.
Levine MA, Downs RW Jr, Moses AM, Breslau NA, Marx SJ, Lasker RD, Rizzoli RE, Aurbach GD, Spiegel AM: Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983;74:545–556.
2.
Levine MA: Pseudohypoparathyroidism: from bedside to bench and back. J Bone Miner Res 1999;14:1255–1260.
3.
Chase LR, Melson GL, Aurbach GD: Pseudohypoparathyroidism: defective excretion of 3′,5′-AMP in response to parathyroid hormone. J Clin Invest 1969;48:1832–1844.
4.
Albright F, Burnett CH, Smith PH, Parson W: Pseudo-hypoparathyroidism – an example of ‘Seabright-Bantam syndrome’: report of three cases. Endocrinology 1942;30:922–932.
5.
Levine MA, Jap TS, Mauseth RS, Downs RW, Spiegel AM: Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine and genetic analysis of Albright’s hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 1986;62:497–502.
6.
Levine MA, Ahn TG, Klupt SF, Kaufman KD, Smallwood PM, Bourne HR, Sullivan KA, Van Dop C: Genetic deficiency of the alpha subunit of the guanine nucleotide-binding protein Gs as the molecular basis for Albright hereditary osteodystrophy. Proc Natl Acad Sci USA 1988;85:617–621.
7.
Linglart A, Carel JC, Garabédian M, Lé T, Mallet E, Kottler ML: GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype-phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J Clin Endocrinol Metab 2002;87:189–197.
8.
Patten JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G, Smallwood PM, Levine MA: Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright’s hereditary osteodystrophy. N Engl J Med 1990;322:1412–1419.
9.
Davies SJ, Hughes HE: Imprinting in Albright’s hereditary osteodystrophy. J Med Genet 1993;30:101–103.
10.
Yu S, Yu D, Lee E, Eckhaus M, Lee R, Corria Z, Accili D, Westphal H, Weinstein LS: Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci USA 1998;95:8715–8720.
11.
Germain-Lee EL, Schwindinger W, Crane JL, Zewdu R, Zweifel LS, Wand G, Huso DL, Saji M, Ringel MD, Levine MA: A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the GNAS gene. Endocrinology 2005;146:4697–4709.
12.
Liu J, Erlichman B, Weinstein LS: The stimulatory G protein subunit Gs is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 2003;88:4336–4341.
13.
Bastepe M, Jüppner H: Pseudohypoparathyroidism: new insights into an old disease. Endocrinol Metab Clin North Am 2000;29:569–589.
14.
Jan De Beur SM, O’Connell JR, Peila R, Cho J, Deng Z, Kam S, Levine MA: The pseudohypoparathyroidism type Ib locus is linked to a region including GNAS1 at 20q13.3. J Bone Miner Res 2003;18:424–433.
15.
Liu J, Litman D, Rosenberg MJ, Yu S, Biesecker LG, Weinstein LS: A GNAS1 imprinting defect in pseudohypoparathyroidism type Ib. J Clin Invest 2000;106:1167–1174.
16.
Bastepe M, Fröhlich LE, Hendy GN, Indridason OS, Josse RG, Koshiyama H, Korkko J, Nakamoto JM, Rosenbloom AL, Slyper AH, Sugimoto T, Tsatsoulis A, Crawford JD, Jüppner H: Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003;112:1255–1263.
17.
Levine MA: Parathyroid hormone resistance syndromes; in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 4. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 230–235.
18.
Weinstein LS, Gejman PV, Friedman E, Kadowaki T, Collins RM, Gershon ES, Spiegel AM: Mutations of the Gs subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1990;87:8287–8290.
19.
Miric A, Vechio JD, Levine MA: Heterogeneous mutations in the gene encoding the subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 1993;76:1560–1568.
20.
Breslau NA, Notman DD, Canterbury JM, Moses AM: Studies on the attainment of normocalcemia in patients with pseudohypoparathyroidism. Am J Med 1980;68:856–860.
21.
Weinstein LS, Yu S, Ecelbarger CA: Variable imprinting of the heterotrimeric G protein Gs subunit within different segments of the nephron. Am J Physiol 2000;278:F507–F514.
22.
Stone MD, Hosking DJ, Garcia-Himmelstine C, White DA, Rosenblum D, Worth HG: The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993;14:727–735.
23.
Bourdeau JE, Burg MB: Effect of PTH on calcium transport across the cortical thick ascending limb of Henle’s loop. Am J Physiol 1980;239:F121–F126.
24.
Weisman Y, Golander A, Spirer Z, Farfel Z: Pseudohypoparathyroidism type Ia presenting as congenital hypothyroidism. J Pediatr 1985;107:413–415.
25.
Levine MA, Jap TS, Hung W: Infantile hypothyroidism in two sibs: an unusual presentation of pseudohypoparathyroidism type Ia. J Pediatr 1985;107:919–922.
26.
Namnoum AB, Merriam GR, Moses AM, Levine MA: Reproductive dysfunction in women with Albright’s hereditary osteodystrophy. J Clin Endocrinol Metab 1998;83:824–829.
27.
Scott DC, Hung W: Pseudohypoparathyroidism type Ia and growth hormone deficiency in two siblings. J Pediatr Endocrinol Metab 1995;8:205–207.
28.
Urdanivia E, Mataverde A, Cohen MP: Growth hormone secretion and sulfation factor activity in pseudohypoparathyroidism. J Lab Clin Med 1975;86:772–776.
29.
Mantovani G, Maghnie M, Weber G, De Menis E, Brunelli V, Cappa M, Loli P, Beck-Peccoz P, Spada A: Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gsα gene. J Clin Endocrinol Metab 2003;88:4070–4074.
30.
Germain-Lee EL, Groman J, Crane JL, Jan de Beur SM, Levine MA: Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab2003;88:4059–4069.
31.
Laspa E, Bastepe M, Jüppner H, Tsatsoulis A: Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance J Clin Endocrinol Metab 2004;89:5942–5947.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.